晚期胰腺癌治疗现状与进展  

Research advances in treatment of metastatic pancreatic cancer

作　　者：崔瀚之[1,3] 杜丽文 樊梦娇 吴超[1] 司海燕[1] 戴广海[1] CUI Hanzhi;DU Liwen;FAN Mengjiao;WU Chao;SI Haiyan;DAI Guanghai(Department of Oncology,the First Medical Center,Chinese PLA General Hospital,Beijing 100853,China;Department of Oncology,People's Hospital in Lanling,Linyi 277799,Shandong Province,China;Department of Oncology,the Eighth Medical Center,Chinese PLA General Hospital,Beijing 100091,China)

机构地区：[1]解放军总医院第一医学中心肿瘤内科,北京100853 [2]兰陵县人民医院肿瘤内科,山东临沂277799 [3]解放军总医院第八医学中心肿瘤科,北京100091

出　　处：《解放军医学院学报》2020年第9期926-929,共4页Academic Journal of Chinese PLA Medical School

基　　金：国家自然科学基金面上项目(31671298)。

摘　　要：胰腺癌是一种常见的消化系统恶性肿瘤,恶性程度高,预后差,5年生存率仅5%。近年来,胰腺癌的发病率呈逐年升高的趋势。胰腺癌早期多无明显的临床症状与体征,确诊时往往已有远处转移,无法行手术治疗。目前,晚期胰腺癌的治疗策略仍是以化疗为主的综合治疗。但随着对胰腺癌分子生物学及其微环境特征的深入研究,基于分子分型的精准治疗、个体化治疗或许可以给晚期胰腺癌患者带来一丝曙光。本文结合近年来发表的相关文献,对晚期胰腺癌的治疗现状和进展进行综述。Pancreatic cancer is a kind of lethal digestive system malignant tumor with poor prognosis,with a 5-year survival rate of 5%.In recent years,due to the improvement of living standard and the change of life style,the incidence of pancreatic cancer is increasing year by year,which seriously threatens people’s health.Showing no obvious clinical symptoms and signs in the early stage,majority of patients with pancreatic cancer can not be diagnosed in time and receive curative therapy.Therefore,the treatment strategy of advanced pancreatic cancer is still chemotherapy-based combination treatment.But with the development of the molecular biology research in pancreatic cancer and its micro-environmental characteristics,precised and individualized treatment based on gene diagnosis may bring a light to patients with advanced pancreatic cancer.Here we review the advances in the treatment of metastatic pancreatic cancer according to the latest literatures.

关 键 词：胰腺癌 化疗 免疫治疗 精准治疗 进展 

分 类 号：R735.9[医药卫生—肿瘤]